{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:56:24Z","timestamp":1791233784885,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":52,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s13311-023-01416-x","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T13:02:20Z","timestamp":1690894940000},"page":"1275-1283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dimethyl Fumarate or Teriflunomide for Relapsing\u2013Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-6267","authenticated-orcid":false,"given":"Luca","family":"Prosperini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalom","family":"Haggiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Tortorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-023-01416-x_bib1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","article-title":"Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis","volume":"15","author":"Rotstein","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-023-01416-x_bib2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1212\/WNL.0000000000008319","article-title":"Head-to-head drug comparisons in multiple sclerosis: urgent action needed","volume":"93","author":"Tur","year":"2019","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01416-x_bib3","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","article-title":"Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs glatiramer acetate in relapsing MS disease [REGARD] study): a multicentre, randomised, parallel, open-label trial","volume":"7","author":"Mikol","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-023-01416-x_bib4","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/01.wnl.0000345970.73354.17","article-title":"Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study","volume":"72","author":"Cadavid","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01416-x_bib5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","article-title":"250 \u03bcg or 500 \u03bcg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study","volume":"8","author":"O'Connor","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-023-01416-x_bib6","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"13","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-023-01416-x_bib7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-023-01416-x_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1007\/s13311-023-01416-x_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1007\/s13311-023-01416-x_bib10","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"14","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1007\/s13311-023-01416-x_bib11","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","article-title":"(2022) Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial","volume":"21","author":"Svenningsson","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-023-01416-x_bib12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-023-01416-x_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1007\/s13311-023-01416-x_bib14","article-title":"Using PICO to align medical evidence with MDs decision making models","volume":"192","author":"O'Sullivan","year":"2013","journal-title":"Stud Health Technol Inform"},{"key":"10.1007\/s13311-023-01416-x_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/ebmental-2019-300129","article-title":"Challenges in meta-analyses with observational studies","volume":"23","author":"Metelli","year":"2020","journal-title":"Evid Based Ment Health"},{"key":"10.1007\/s13311-023-01416-x_bib16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1007\/s13311-023-01416-x_bib17","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/biom.13197","article-title":"Optimal approximate conversions of odds ratios and hazard ratios to risk ratios","volume":"76","author":"VanderWeele","year":"2020","journal-title":"Biometrics"},{"key":"10.1007\/s13311-023-01416-x_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40120-017-0064-x","article-title":"Comparative effectiveness research of disease-modifying therapies for the management of multiple sclerosis: analysis of a large health insurance claims database","volume":"6","author":"Boster","year":"2017","journal-title":"Neurol Ther"},{"key":"10.1007\/s13311-023-01416-x_bib19","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1007\/s00415-018-9083-5","article-title":"Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry","volume":"265","author":"Braune","year":"2018","journal-title":"J Neurol"},{"key":"10.1007\/s13311-023-01416-x_bib20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/ene.13839","article-title":"Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study","volume":"26","author":"Cond\u00e9","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-023-01416-x_bib21","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1007\/s00415-020-09959-1","article-title":"Dimethyl fumarate vs teriflunomide: an Italian time-to-event data analysis","volume":"267","author":"D'Amico","year":"2020","journal-title":"J Neurol"},{"key":"10.1007\/s13311-023-01416-x_bib22","doi-asserted-by":"crossref","first-page":"e1811","DOI":"10.1212\/WNL.0000000000007314","article-title":"Comparative effectiveness of teriflunomide and dimethyl fumarate: a nationwide cohort study","volume":"92","author":"Buron","year":"2019","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01416-x_bib23","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1007\/s00415-020-09811-6","article-title":"Oral therapies for treatment of relapsing\u2013remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method","volume":"267","author":"Guger","year":"2020","journal-title":"J Neurol"},{"key":"10.1007\/s13311-023-01416-x_bib24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/13524585211019649","article-title":"A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry","volume":"28","author":"Hillert","year":"2022","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-023-01416-x_bib25","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/jnnp-2018-319831","article-title":"Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis","volume":"90","author":"Kalincik","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-023-01416-x_bib26","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1212\/WNL.0000000000007938","article-title":"Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis","volume":"93","author":"Laplaud","year":"2019","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01416-x_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/6679197","article-title":"Comparable efficacy and safety of teriflunomide versus dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis","volume":"2021","author":"Nehzat","year":"2021","journal-title":"Neurol Res Int"},{"key":"10.1007\/s13311-023-01416-x_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.msard.2018.09.038","article-title":"Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US","volume":"27","author":"Ontaneda","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1007\/s13311-023-01416-x_bib29","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00415-019-09625-1","article-title":"Exit strategies for \u201cneedle fatigue\u201d in multiple sclerosis: a propensity score-matched comparison study","volume":"267","author":"Prosperini","year":"2020","journal-title":"J Neurol"},{"key":"10.1007\/s13311-023-01416-x_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102521","article-title":"An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014\u20132017","volume":"46","author":"Vermersch","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1007\/s13311-023-01416-x_bib31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2217\/cer-2018-0135","article-title":"Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study","volume":"8","author":"Zivadinov","year":"2019","journal-title":"J Comp Eff Res"},{"issue":"Suppl 1","key":"10.1007\/s13311-023-01416-x_bib32","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0022-510X(11)70007-7","article-title":"Review of methodological issues of clinical trials in multiple sclerosis","volume":"311","author":"Montalban","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-023-01416-x_bib33","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1007\/s00415-021-10455-3","article-title":"Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study","volume":"268","author":"Bucello","year":"2021","journal-title":"J Neurol"},{"key":"10.1007\/s13311-023-01416-x_bib34","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1093\/brain\/awx185","article-title":"Towards personalized therapy for multiple sclerosis: prediction of individual treatment response","volume":"140","author":"Kalincik","year":"2017","journal-title":"Brain"},{"key":"10.1007\/s13311-023-01416-x_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7224\/1537-2073.2014-101","article-title":"Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE)","volume":"18","author":"Fox","year":"2016","journal-title":"Int J MS Care"},{"key":"10.1007\/s13311-023-01416-x_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","article-title":"Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study","volume":"34","author":"Naismith","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-023-01416-x_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.MR000034.pub2","article-title":"Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials","author":"Anglemyer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-023-01416-x_bib38","first-page":"343","article-title":"The ecological fallacy","author":"Sedgwick","year":"2011","journal-title":"BMJ"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01416-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-023-01416-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01416-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:12:17Z","timestamp":1761808337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923019268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1878747923019268"],"URL":"https:\/\/doi.org\/10.1007\/s13311-023-01416-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3025385\/v1","asserted-by":"object"}]},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dimethyl Fumarate or Teriflunomide for Relapsing\u2013Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-023-01416-x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}